Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI

BioMarin Pharmaceutical Inc., Novato, California, United States

The purpose of the study is to evaluate the safety, efficacy and pharmacokinetics of two dose levels of weekly intravenous infusions of recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) for a minimum of 24 weeks in patients diagnosed with MPS VI.